Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Baerbel, Rotthaeuser"'
Autor:
Mandy Mohnicke, Arnd Blecher, Kathrin Beichert, Bernd Bidlingmaier, Ernst-Josef Todt, Christoph Dette, Baerbel Rotthaeuser, Bhaswati Mukherjee
Publikováno v:
Journal of Pharmaceutical Sciences. 112:963-973
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2000ae68ca13dc8410aff43d770af859
https://doi.org/10.1016/j.xphs.2022.12.006
https://doi.org/10.1016/j.xphs.2022.12.006
Autor:
S. R. Aravind, Kiran P. Singh, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Publikováno v:
Diabetes Therapy. 13:1299-1310
We compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (70% intermediate SAR341402 protamine and 30% rapid SAR341402 solution) (SARThis phase 3, randomized, open-label, multinational, 26-week tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0caa3cbb19b79639d8e3fe739120f26b
https://doi.org/10.1007/s13300-022-01279-z
https://doi.org/10.1007/s13300-022-01279-z
Autor:
Mandy, Mohnicke, Arnd, Blecher, Kathrin, Beichert, Bernd, Bidlingmaier, Ernst-Josef, Todt, Christoph, Dette, Baerbel, Rotthaeuser, Bhaswati, Mukherjee
Publikováno v:
Journal of pharmaceutical sciences.
SAR341402 (Insulin aspart Sanofi®) is an insulin aspart biosimilar that can be used for continuous subcutaneous insulin infusion (CSII) in pump systems. The physicochemical stability of SAR341402 for CSII use was evaluated in several in vitro experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::316074e8d1539f91253318c5bff289c8
https://pubmed.ncbi.nlm.nih.gov/36521561
https://pubmed.ncbi.nlm.nih.gov/36521561
Autor:
Viswanathan, Mohan, Wolfgang, Schmider, Kiran P, Singh, Baerbel, Rotthaeuser, Bhaswati, Mukherjee, S R, Aravind
Publikováno v:
Indian journal of endocrinology and metabolism. 26(4)
We compared the pharmacokinetic exposure, efficacy, safety and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARThis was a randomized, open-label, parallel-group, substudy of the phase 3 GEMELLI M trial performed in three In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::907a679ad50e5ec5094be3eb23d0a403
https://pubmed.ncbi.nlm.nih.gov/36185965
https://pubmed.ncbi.nlm.nih.gov/36185965
Autor:
S. R. Aravind, Kiran P. Singh, Grace Aquitania, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Publikováno v:
Diabetes therapy : research, treatment and education of diabetes and related disorders. 13(5)
This study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARThis 26-week, open-label, phase 3 trial enrolled 402 people with T1D (n = 105) or T2D (n = 297) previously treated with premix in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bebbeff4fe4b05ba639824f46cddc001
https://pubmed.ncbi.nlm.nih.gov/35420397
https://pubmed.ncbi.nlm.nih.gov/35420397
Autor:
Satish K. Garg, James Thrasher, Karin Wernicke-Panten, Baerbel Rotthaeuser, Howard Surks, Suzanne Pierre, Irene Nowotny
Publikováno v:
Journal of Diabetes Science and Technology
Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics between the two products has been demonstrated in a hyperinsulinemic euglycemic clamp study. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55144604e5779947526c56264736cb60
http://europepmc.org/articles/PMC6154226
http://europepmc.org/articles/PMC6154226
Autor:
Anne Lehmann, Karin Bergmann, Baerbel Rotthaeuser, Reinhard H.A. Becker, Irene Nowotny, Christoph Kapitza, Leszek Nosek
Publikováno v:
Diabetes, Obesity and Metabolism. 19:622-627
Aim To compare the pharmacokinetics (PK) and pharmacodynamics (PD) of 3 rapid-acting insulin lispro products: SAR342434 solution, United States (US)-approved Humalog and European Union (EU)-approved Humalog. Methods In a single-centre, randomized, do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04cc21a1e1c751c141170e50444bbc95
https://doi.org/10.1111/dom.12856
https://doi.org/10.1111/dom.12856
Autor:
Anne Lehmann, Irene Nowotny, Leszek Nosek, Christoph Kapitza, Wolfgang Schmider, Baerbel Rotthaeuser
Publikováno v:
Diabetes. 68
SAR341402 (SAR-Asp), NovoLog (NN-Asp-US) and NovoRapid (NN-Asp-EU) are rapid-acting insulin aspart products. Exposure (PK) to and activity (PD) of SAR-Asp (T) NN-Asp-US (R1) and NN-Asp-EU (R2) were compared in a single-center, randomized, double-blin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a453a2ceccf972f76d7b2904df51b7
https://doi.org/10.2337/db19-130-lb
https://doi.org/10.2337/db19-130-lb